CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 25 enrolled
Drug / intervention
Dexrazoxanedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03930680
NCT03930680Phase 1Completed
CompareCT.gov

Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane in Patients With Breast Cancer

University of Arkansas·interventional·Posted Apr 29, 2019·Updated Jul 8, 2025

In Brief

A Phase 1 clinical trial evaluating Dexrazoxane for Degradation of Top2b and Top2a in Human by Dexrazoxane and 2 related conditions. Completed, enrolled 25 participants across 1 site.

Detailed Summary

The purpose of this research study is to determine whether early administration of Dexrazoxane prevents Doxorubicin induced cardiotoxicity.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDegradation of Top2b and Top2a in Human by Dexrazoxane, Time Course and Degradation of Top2b in Human by Dexrazoxane, Effects of Dexrazoxane on Healthy Human
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)

Timeline

Phase 1CompletedFinished
2020202120222023202420252026
First PostedApr 29, 2019
Enrollment StartSep 14, 2021
Primary CompletionJun 11, 2024
Study CompletionJun 11, 2025
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 7.2 years ago

Interventions

Dexrazoxanedrug

One dose of dexrazoxane